Immatics Z Score
IMTX Stock  USD 9.78 0.00 0.00% 
Immatics  Z Score 
Immatics Z Score Analysis
Immatics' ZScore is a simple linear, multifactor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
More About Z Score  All Equity Analysis
2020  2021  2022  2023 (projected)  
Current Assets  238.99 M  152.21 M  377.15 M  308.23 M 
Total Assets  254.65 M  174.65 M  407.82 M  334.22 M 
Z Score  =  Sum Of   5 Factors 
Current Immatics Z Score  27.49 
Most of Immatics' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immatics NV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
 
 
 
 

Immatics Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Immatics is extremely important. It helps to project a fair market value of Immatics Stock properly, considering its historical fundamentals such as Z Score. Since Immatics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immatics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immatics' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a ZScore, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. ZScores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with ZScores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a socalled 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize zscores proved it to be successful as a predictor of corporate bankruptcy.
Competition 
According to the company's disclosures, Immatics NV has a Z Score of 27.49. This is 307.26% higher than that of the Healthcare sector and notably higher than that of the Biotechnology industry. The z score for all United States stocks is notably lower than that of the firm.
Immatics Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immatics' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immatics could also be used in its relative valuation, which is a method of valuing Immatics by comparing valuation metrics of similar companies.Immatics is currently under evaluation in z score category among related companies.
Immatics Fundamentals
Return On Equity  (0.43) %  
Return On Asset  (0.12) %  
Profit Margin  (0.85) %  
Operating Margin  (0.81) %  
Current Valuation  427.48 M  
Shares Outstanding  76.67 M  
Shares Owned by Insiders  26.02 %  
Shares Owned by Institutions  46.77 %  
Number of Shares Shorted  4.42 M  
Price to Earning  44.61 X  
Price to Book  6.18 X  
Price to Sales  4.70 X  
Revenue  172.83 M  
Gross Profit  172.83 M  
EBITDA  46.34 M  
Net Income  37.51 M  
Cash and Equivalents  324.38 M  
Cash per Share  5.00 X  
Total Debt  16.41 M  
Debt to Equity  0.13 %  
Current Ratio  2.95 X  
Book Value Per Share  2.61 X  
Cash Flow from Operations  100.13 M  
Short Ratio  8.34 X  
Earnings Per Share  (1.19) X  
Price to Earnings To Growth  3.00 X  
Target Price  18.02  
Number of Employees  402  
Beta  0.48  
Market Capitalization  755.21 M  
Total Asset  407.82 M  
Retained Earnings  (500.3 M)  
Working Capital  270.7 M  
Z Score  27.49  
Net Asset  407.82 M 
About Immatics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immatics NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immatics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immatics NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Immatics N.V., a clinicalstage biopharmaceutical company, focuses on the discovery and development of T cell receptor based immunotherapies for the treatment of cancer in the United States. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications MD Anderson Cancer Center to develop multiple T cell and TCRbased adoptive cellular therapies Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers and Genmab AS to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 388 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immatics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immatics' short interest history, or implied volatility extrapolated from Immatics options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immatics NV using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Immatics Piotroski F Score and Immatics Valuation analysis. You can also try Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for Immatics Stock analysis
When running Immatics' price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk  
Technical Analysis Check basic technical indicators and analysis based on most latest market data  
Bond Directory Find actively traded corporate debentures issued by US companies  
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges  
ETF Directory Find actively traded Exchange Traded Funds (ETF) from around the world  
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and roboadvisors.  
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators  
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device  
Commodity Channel Index Use Commodity Channel Index to analyze current equity momentum  
RiskReturn Analysis View associations between returns expected from investment and the risk you assume  
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities  
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account  
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets 
Is Immatics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immatics. If investors know Immatics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immatics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.19)  Revenue Per Share 1.128  Quarterly Revenue Growth (0.91)  Return On Assets (0.12)  Return On Equity (0.43) 
The market value of Immatics NV is measured differently than its book value, which is the value of Immatics that is recorded on the company's balance sheet. Investors also form their own opinion of Immatics' value that differs from its market value or its book value, called intrinsic value, which is Immatics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immatics' market value can be influenced by many factors that don't directly affect Immatics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immatics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immatics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immatics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party. Check out Immatics Piotroski F Score and Immatics Valuation analysis.